This is where I have to decide: am I just interpreting the news favorably because I need some good news? Or is it actually good?
It’s a mixed bag.
I am thrilled that there is a drug for the treatment of COVID, which can decrease the symptoms and speed recovery. Merck’s Phase 3 study of molnupiravir showed a 50% reduction in hospitalization and death, which is dramatic. This investigational drug is already emergency-authorized in the UK, and is being reviewed for use in the US.
UK authorizes Merck antiviral pill, 1st shown to treat COVID
LONDON (AP) — Britain granted conditional authorization on Thursday to the first pill shown to successfully treat COVID-19 so far. It also is the first country to OK the treatment from drugmaker Merck, although it wasn’t immediately clear how quickly the pill would be available.
I’m looking forward to seeing it on the US FDA’s list of emergency authorizations for this crisis. (The list is a bit depressing, because you see statements like that first footnote: “1 The virus that causes COVID-19 has led to an increased number of patients requiring critical care, such as with severe respiratory illness. As a result, there is a shortage of adequate, FDA-approved drugs used for their treatment, such as propofol for sedation of mechanically ventilated patients.” The idea that there is a shortage of common sedatives because of this crisis is a reminder of how broad the impacts are…)
We need more where that came from! There are other medicines in the pipeline, which I get to read about in the local pharma news summaries, and while reading about a vaccine company where a friend works. I would like this progress to be celebrated more widely, or at least recognized, though I understand that the emphasis is, and should be, on getting everyone vaccinated. (Additional vaccines are in development, also!)
My European friends are frustrated. Cases are shooting up in Europe (Germany is setting new 50k daily records (my friends there complain about the inconsistent and seemingly performative guidance there), and the Netherlands are considering another light lockdown as hospitals fill (my friend there wants to go to some educational events, and is hoping that will still be possible).
Since I’m writing from the country with the highest cumulative number of cases and deaths, I see lots of reasons for optimism elsewhere, because other countries are doing so well relative to us!! [Laugh/cry here]. A country with a fraction of our infection rate is high on my tourist destination list, and I hope they will open for vaccinated tourism in early 2022 so I can go.
~ * ~
These zoonotic diseases continue to make me resent consumers of animals, who bring these illnesses into human populations and affect all of us.
One of the stranger articles on the animal-impact theme is that Americans are infecting deer with COVID, and the illness is now raging through deer populations without our noticing. Which is just another population for it to potentially mutate in…
I wish humans learned faster!
~ * ~
My daily life is relatively conventional now, in terms of being able to get where I need to go on transit, being able to keep supplied in basic household goods, getting medical appointments for routine check ups, and such.
My City isn’t fully recovered. There are still many boarded-up storefronts. There are still For Lease signs up in even those posh shopping districts with brands I’ve never understood. (You can see all the way through some fancy shops and out into Maiden Lane in spaces that have not been vacant in my lifetime…) There is still a fleet of “recreational vehicles” serving as housing at unprecedented densities in certain locations. There are still too few shelters for the people who need them, with prior progress being undone by health distancing requirements. Some hotels and restaurants remain closed, especially those that catered to professional conferences in my once-conference-filled town.
The impacts of evolving remote work policies will also take a long time to sort out.
~ * ~
I’m happy for the new medicines, the flexibility the FDA has shown, the large number of medicines still in development, and regional improvements in infection rates. I’ll try to dwell on these things.